Trial Profile

A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doravirine/islatravir (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide
Indications HIV-1 infections
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms MK-8591A-020
Sponsors Merck Sharp & Dohme Corp.

24 Feb 2025 Status changed from suspended to completed.
22 May 2024 This trial has been completed in Germany according to European Clinical Trials Database record.
01 Nov 2022 Planned End Date changed from 9 Dec 2024 to 3 Mar 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com